Banarian Nordic Res (BVNKF) 19.4600 $BVNKF
Smallpox Therapeutics Pipeline Review Report 2014 - 15 Companies & 16 Drug Profiles
M2 - Wed Sep 10, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hdcds3/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Symphogen A/S - Nanotherapeutics, Inc. - CEL-SCI Corporation - SIGA Technologies, Inc. - TapImmune Inc. - CJ CheilJedang Corp. - MacroGenics, Inc. - AlphaVax, Inc. - EpiVax, Inc. - Chimerix, Inc. - Conkwest, Inc. - Inhibikase Therapeutics, Inc. - Polyrizon Ltd. Drug Profiles - smallpox vaccine [Modified Vaccinia Ankara - Bavarian Nordic Virus] - CJ-50300 - brincidofovir - Sym-002 - cidofovir - CEL-1000 - tecovirimat - DNA Vaccine for Smallpox - Smallpox Vaccine - CST-102 - DNA Vaccine for Smallpox - TPIV-300 - imatinib mesylate - Monoclonal Antibody for Infectious Disease - PL-801 - Smallpox Vaccine For more information visit http://www.researchandmarkets.com/research/hdcds3/smallpox
Global Ebola and Marburg Infections Therapeutics Pipeline Report 2014 - 10 Companies & 12 Drug Profiles
M2 - Tue Sep 09, 9:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gjrkc2/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ebola and Marburg Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Crucell N.V. - NanoViricides, Inc. - AlphaVax, Inc. - Immunovaccine, Inc. - Integrated BioTherapeutics, Inc. - Profectus BioSciences, Inc. - Mapp Biopharmaceutical, Inc. Drug Profiles - Vaccine for Multivalent Filovirus - Ebola Vaccine Marburg Vaccine - Vaccine For Filovirus - Ebola/Marburg Program - Ebola And Marburg Vaccine - Monoclonal Antibody for Marburg Virus - Polyvalent DNA Vaccine for Ebola and Marburg Filoviruses - MVA-BN-Filoviruses Vaccine - rVSV-Vectored Vaccines - Subunit Vaccine for Multifiloviruses - Monoclonal Antibodies to Inhibit Glycoprotein for Marburg Virus Infection - Monoclonal Antibodies for Ebola and Marburg Infections For more information visit http://www.researchandmarkets.com/research/gj...nd_marburg
Bavarian Nordic Announces Exercise of Contract Option by the U.S. Government for Continued Supply of IMVAMUNE(r) Smallpox Vaccine
GlobeNewswire - Thu Sep 04, 11:19AM CDT
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health & Human Services (HHS) has exercised an option valued at USD 118 million for the continued delivery of IMVAMUNE smallpox vaccine to the U.S. Strategic National Stockpile (SNS).
Bavarian Nordic Accelerates Ebola Vaccine Development Programs in Collaboration with the U.S. National Institutes of Health
GlobeNewswire - Wed Sep 03, 11:25PM CDT
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that it will accelerate its collaboration with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), on the development of its Ebola vaccine programs. Bavarian Nordic and partners are planning to initiate the first trial of a promising combination vaccine regimen in humans in 2015.
Bavarian Nordic Announces First Half 2014 Results
GlobeNewswire - Thu Aug 28, 1:09AM CDT
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today publishes its interim financial results for the first half of 2014.
Bavarian Nordic Receives Order From the Canadian Government to Supply IMVAMUNE(R) Smallpox Vaccine
GlobeNewswire - Tue Aug 26, 1:08AM CDT
Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today that it has signed two contracts with the Canadian authorities for the delivery of a total of 65,700 doses of IMVAMUNE smallpox vaccine. The vaccines will be delivered in 2014 and 2015. This will bring the current number of delivered doses of IMVAMUNE to Canada above 100,000 doses.
Bavarian Nordic Announces First Patient Treated in a Phase 1 Study of MVA-BN(r) Brachyury in Advanced Cancer
GlobeNewswire - Thu Jul 24, 12:57AM CDT
Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today that the first patient has been treated in an NCI-sponsored Phase 1 study of MVA-BN Brachyury in patients with advanced cancer.
Bavarian Nordic to Participate in European Midcap Event in Paris
Thomson Reuters ONE - Tue Jun 24, 1:04AM CDT
KVISTGAARD, Denmark - June 24, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that Rolf Sass Sorensen, Vice President Investor Relations & Communications will participate in the European Midcap Event "Spring" in Paris on June 26-27, 2014.
Smallpox - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ndtlnz/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Smallpox - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Mentioned: - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Symphogen A/S - Nanotherapeutics, Inc. - CEL-SCI Corporation - GeoVax Labs, Inc. - SIGA Technologies, Inc. - TapImmune Inc. - CJ CheilJedang Corp. - MacroGenics, Inc. - AlphaVax, Inc. - EpiVax, Inc. - Chimerix, Inc. - NanoBio Corporation - Conkwest, Inc. For more information visit http://www.researchandmarkets.com/research/ndtlnz/smallpox
Bavarian Nordic A/S - Notice Convening Ordinary General Meeting
Thomson Reuters ONE - Thu Mar 27, 4:05AM CDT
Pursuant to Article 10 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the ordinary General Meeting to be held on
Bavarian Nordic Announces 2013 Full Year Results
GlobeNewswire - Wed Mar 19, 2:43AM CDT
Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) today published its 2013 annual report. Revenue was DKK 1,213 million / USD 224 million (DKK 1,017 million / USD 188 million in 2012). The Group recorded a profit before tax of DKK 6 million / USD 1 million (DKK 49 million loss / USD 9 million loss in 2012). Revenue and results were in line with the expectations for the year. As planned, the Company delivered 7 million doses of IMVAMUNE(R) to the U.S. in 2013, of which 1.4 million doses relate to the new contract that was entered in April 2013.
Bavarian Nordic to Host Full Year 2013 Results Conference Call
Thomson Reuters ONE - Thu Mar 13, 11:30AM CDT
KVISTGAARD, Denmark - March 13, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2013 full year results on Wednesday, March 19, 2014.
Bavarian Nordic's MVA-BN(R) Vaccine Platform Selected by U.S. Department of Defense for New Vaccine Development
GlobeNewswire - Fri Feb 21, 3:25AM CST
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that its MVA-BN vaccine platform technology has been selected by the Defense Threat Reduction Agency (DTRA), a part of the United States Department of Defense, for the development of a vaccine against two potential biological threats to national security - Burkholderia pseudomallei and Burkholderia mallei.
Smallpox Therapeutics Pipeline Review Report 2014 - 15 Companies & 16 Drug Profiles
M2 - Wed Sep 10, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hdcds3/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Symphogen A/S - Nanotherapeutics, Inc. - CEL-SCI Corporation - SIGA Technologies, Inc. - TapImmune Inc. - CJ CheilJedang Corp. - MacroGenics, Inc. - AlphaVax, Inc. - EpiVax, Inc. - Chimerix, Inc. - Conkwest, Inc. - Inhibikase Therapeutics, Inc. - Polyrizon Ltd. Drug Profiles - smallpox vaccine [Modified Vaccinia Ankara - Bavarian Nordic Virus] - CJ-50300 - brincidofovir - Sym-002 - cidofovir - CEL-1000 - tecovirimat - DNA Vaccine for Smallpox - Smallpox Vaccine - CST-102 - DNA Vaccine for Smallpox - TPIV-300 - imatinib mesylate - Monoclonal Antibody for Infectious Disease - PL-801 - Smallpox Vaccine For more information visit http://www.researchandmarkets.com/research/hdcds3/smallpox
Global Ebola and Marburg Infections Therapeutics Pipeline Report 2014 - 10 Companies & 12 Drug Profiles
M2 - Tue Sep 09, 9:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gjrkc2/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ebola and Marburg Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Crucell N.V. - NanoViricides, Inc. - AlphaVax, Inc. - Immunovaccine, Inc. - Integrated BioTherapeutics, Inc. - Profectus BioSciences, Inc. - Mapp Biopharmaceutical, Inc. Drug Profiles - Vaccine for Multivalent Filovirus - Ebola Vaccine Marburg Vaccine - Vaccine For Filovirus - Ebola/Marburg Program - Ebola And Marburg Vaccine - Monoclonal Antibody for Marburg Virus - Polyvalent DNA Vaccine for Ebola and Marburg Filoviruses - MVA-BN-Filoviruses Vaccine - rVSV-Vectored Vaccines - Subunit Vaccine for Multifiloviruses - Monoclonal Antibodies to Inhibit Glycoprotein for Marburg Virus Infection - Monoclonal Antibodies for Ebola and Marburg Infections For more information visit http://www.researchandmarkets.com/research/gj...nd_marburg
Bavarian Nordic Announces Exercise of Contract Option by the U.S. Government for Continued Supply of IMVAMUNE(r) Smallpox Vaccine
GlobeNewswire - Thu Sep 04, 11:19AM CDT
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health & Human Services (HHS) has exercised an option valued at USD 118 million for the continued delivery of IMVAMUNE smallpox vaccine to the U.S. Strategic National Stockpile (SNS).
Bavarian Nordic Accelerates Ebola Vaccine Development Programs in Collaboration with the U.S. National Institutes of Health
GlobeNewswire - Wed Sep 03, 11:25PM CDT
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that it will accelerate its collaboration with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), on the development of its Ebola vaccine programs. Bavarian Nordic and partners are planning to initiate the first trial of a promising combination vaccine regimen in humans in 2015.
Bavarian Nordic Announces First Half 2014 Results
GlobeNewswire - Thu Aug 28, 1:09AM CDT
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today publishes its interim financial results for the first half of 2014.
Bavarian Nordic Receives Order From the Canadian Government to Supply IMVAMUNE(R) Smallpox Vaccine
GlobeNewswire - Tue Aug 26, 1:08AM CDT
Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today that it has signed two contracts with the Canadian authorities for the delivery of a total of 65,700 doses of IMVAMUNE smallpox vaccine. The vaccines will be delivered in 2014 and 2015. This will bring the current number of delivered doses of IMVAMUNE to Canada above 100,000 doses.
Bavarian Nordic Announces First Patient Treated in a Phase 1 Study of MVA-BN(r) Brachyury in Advanced Cancer
GlobeNewswire - Thu Jul 24, 12:57AM CDT
Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today that the first patient has been treated in an NCI-sponsored Phase 1 study of MVA-BN Brachyury in patients with advanced cancer.
Bavarian Nordic to Participate in European Midcap Event in Paris
Thomson Reuters ONE - Tue Jun 24, 1:04AM CDT
KVISTGAARD, Denmark - June 24, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that Rolf Sass Sorensen, Vice President Investor Relations & Communications will participate in the European Midcap Event "Spring" in Paris on June 26-27, 2014.
Smallpox - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ndtlnz/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Smallpox - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Mentioned: - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Symphogen A/S - Nanotherapeutics, Inc. - CEL-SCI Corporation - GeoVax Labs, Inc. - SIGA Technologies, Inc. - TapImmune Inc. - CJ CheilJedang Corp. - MacroGenics, Inc. - AlphaVax, Inc. - EpiVax, Inc. - Chimerix, Inc. - NanoBio Corporation - Conkwest, Inc. For more information visit http://www.researchandmarkets.com/research/ndtlnz/smallpox
Bavarian Nordic A/S - Notice Convening Ordinary General Meeting
Thomson Reuters ONE - Thu Mar 27, 4:05AM CDT
Pursuant to Article 10 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the ordinary General Meeting to be held on
Bavarian Nordic Announces 2013 Full Year Results
GlobeNewswire - Wed Mar 19, 2:43AM CDT
Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) today published its 2013 annual report. Revenue was DKK 1,213 million / USD 224 million (DKK 1,017 million / USD 188 million in 2012). The Group recorded a profit before tax of DKK 6 million / USD 1 million (DKK 49 million loss / USD 9 million loss in 2012). Revenue and results were in line with the expectations for the year. As planned, the Company delivered 7 million doses of IMVAMUNE(R) to the U.S. in 2013, of which 1.4 million doses relate to the new contract that was entered in April 2013.
Bavarian Nordic to Host Full Year 2013 Results Conference Call
Thomson Reuters ONE - Thu Mar 13, 11:30AM CDT
KVISTGAARD, Denmark - March 13, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2013 full year results on Wednesday, March 19, 2014.
Bavarian Nordic's MVA-BN(R) Vaccine Platform Selected by U.S. Department of Defense for New Vaccine Development
GlobeNewswire - Fri Feb 21, 3:25AM CST
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that its MVA-BN vaccine platform technology has been selected by the Defense Threat Reduction Agency (DTRA), a part of the United States Department of Defense, for the development of a vaccine against two potential biological threats to national security - Burkholderia pseudomallei and Burkholderia mallei.
